case_images: PMC3975724_01
case_images: Kidney volume progression in 2 patients treated for 18 months with lanreotide: patient 1, a 22-year-old woman (a), and patient 2, a 27-year-old man (b).
case_images: cru-0004-0018-g01.jpg
case_images: PMC3975724_01_cru-0004-0018-g01.jpg
case_images: F1
case_images: This patient showed substantial improvement, not only in terms of kidney volume (fig. 1a), with a decrease of 18.5% for the left and 13.8% for the right kidney over the 18 months of treatment (equalling a 16% reduction in total kidney volume), but also in terms of blood pressure. This patient showed a more modest improvement, with a reduction of 3.7% in total volume after 18 months of lanreotide administration (fig. 1b).
case_images: Kidney volume progression in 2 patients treated for 12 months with lanreotide: patient 3, a 56-year-old woman (a), and patient 4, a 47-year-old man (b).
case_images: cru-0004-0018-g02.jpg
case_images: PMC3975724_01_cru-0004-0018-g02.jpg
case_images: F2
case_images: Kidney volume (fig. 2) and estimated GFR levels (table 1) are shown for both patients. Since no decrease in kidney volume was observed for this patient (the total volume increased by 1%; fig. 2b), we proposed to increase the treatment dose to 180 mg lanreotide once every 4 weeks.